PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Negative EBIT growth while Biotechnology median is -5.96%. Seth Klarman would check if external or internal factors caused the decline.
-20.40%
Negative operating income growth while Biotechnology median is -6.35%. Seth Klarman would check if structural or cyclical issues are at play.
-19.78%
Negative net income growth while Biotechnology median is -8.24%. Seth Klarman would investigate factors dragging net income down.
12.20%
EPS growth of 12.20% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
12.20%
Diluted EPS growth of 12.20% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
35.62%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
35.62%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Negative OCF growth while Biotechnology median is -3.24%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-10.88%
Negative FCF growth while Biotechnology median is -2.64%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-812.85%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
87.84%
OCF/share CAGR of 87.84% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
86.67%
3Y OCF/share growth of 86.67% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-1279.04%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
88.03%
Net income/share CAGR of 88.03% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
86.27%
3Y net income/share CAGR of 86.27% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1371.24%
Equity/share CAGR of 1371.24% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-83.09%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-60.87%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-34.03%
Negative BV/share change while Biotechnology median is -0.56%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-19.69%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
7.98%
R&D growth far exceeding Biotechnology median. Jim Chanos suspects a potential “throw money at problems” approach or a race for new tech that might not pay off.
58.15%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.